Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$466 Mln
P/E Ratio
--
P/B Ratio
19.27
Industry P/E
--
Debt to Equity
-14.02
ROE
-14.81 %
ROCE
-169.63 %
Div. Yield
0 %
Book Value
--
EPS
-2.95
CFO
$-479.74 Mln
EBITDA
$-557.50 Mln
Net Profit
$-666.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| -7.32 | -17.06 | -3.61 | -30.54 | 9.73 | -16.41 | -- |
|
BSE Sensex*
| 2.23 | 3.07 | 6.14 | 8.49 | 12.08 | 20.30 | 11.40 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
UroGen Pharma (URGN)
| 69.11 | -6.73 | -47.23 | -46.00 | -22.50 | 15.63 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.22 | 25.43 | -- | -79.46 | |
| 1.48 | 138.40 | -- | -23.63 | |
| 2.40 | 109.01 | -- | -103.34 | |
| 1.00 | 23.99 | -- | -- |
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for... pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Read more
President, CEO & Director
Ms. Elizabeth A. Barrett
President, CEO & Director
Ms. Elizabeth A. Barrett
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of UroGen Pharma Ltd (URGN) stood at $ 286 Mln as on 31-Dec-24
The share price of UroGen Pharma Ltd (URGN) is $9.87 (NASDAQ) as of 25-Apr-2025 16:00 EDT. UroGen Pharma Ltd (URGN) has given a return of 9.73% in the last 3 years.
UroGen Pharma Ltd (URGN) has a market capitalisation of $ 466 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of UroGen Pharma Ltd (URGN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the UroGen Pharma Ltd (URGN) and enter the required number of quantities and click on buy to purchase the shares of UroGen Pharma Ltd (URGN).
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
The CEO & director of Ms. Elizabeth A. Barrett. is UroGen Pharma Ltd (URGN), and CFO & Sr. VP is Ms. Elizabeth A. Barrett.
There is no promoter pledging in UroGen Pharma Ltd (URGN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
15
|
|
|
8
|
|
|
5
|
|
|
2
|
| UroGen Pharma Ltd. (URGN) | Ratios |
|---|---|
|
Return on equity(%)
|
342.83
|
|
Operating margin(%)
|
-123.37
|
|
Net Margin(%)
|
-140.35
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of UroGen Pharma Ltd (URGN) was $0 Mln.
$-0.24
(
